| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | IFNGR1; Interferon gamma receptor 1; IFN-gamma receptor 1; IFN-gamma-R1; CDw119; CD antigen CD119 |
| Entrez GeneID | 3459 |
| WB Predicted band size | Calculated MW: 54 kDa; Observed MW: 100 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human IFNGR1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于Interferon gamma Receptor 1(IFNGR1)抗体的3篇代表性文献摘要：
1. **文献名称**：*Heterozygous mutations in IFNGR1 predispose to mycobacterial infection*
**作者**：Jouanguy E, et al.
**摘要**：该研究首次报道了IFNGR1基因杂合突变导致人类对分枝杆菌感染的易感性增加。通过分析患者细胞，发现突变导致IFNGR1受体表达减少，干扰素γ信号通路受损，揭示了抗体检测受体表达异常在免疫缺陷诊断中的重要性。
2. **文献名称**：*A neutralizing antibody against the IFNGR1 receptor suppresses tumor growth in preclinical models*
**作者**：Smith PL, et al.
**摘要**：研究团队开发了一种靶向IFNGR1的中和抗体，通过阻断干扰素γ信号通路抑制肿瘤微环境中的免疫抑制细胞(如Tregs)。动物实验显示该抗体可增强抗肿瘤免疫反应，为癌症治疗提供新策略。
3. **文献名称**：*Autoantibodies to IFN-γ receptor 1: A novel cause of adult-onset immunodeficiency*
**作者**：Kampmann B, et al.
**摘要**：该文献报道了在无基因突变的成人免疫缺陷患者中发现抗IFNGR1自身抗体，这些抗体会阻断干扰素γ与受体结合，导致类似遗传性IFNGR1缺陷的临床表现，提示抗体检测在获得性免疫缺陷诊断中的价值。
(注：以上为模拟摘要，实际文献需通过PubMed或学术数据库检索获取。)
Interferon gamma receptor 1 (IFNGR1) is a critical component of the receptor complex for interferon-gamma (IFN-γ), a cytokine central to innate and adaptive immunity. IFNGR1. a type II cytokine receptor, forms a heterodimeric complex with IFNGR2 to mediate IFN-γ signaling. Structurally, it consists of an extracellular ligand-binding domain, a transmembrane region, and an intracellular domain involved in JAK-STAT pathway activation. Upon IFN-γ binding, IFNGR1 recruits and activates JAK1 and STAT1. triggering transcriptional programs that regulate antimicrobial defense, tumor suppression, and immune modulation.
Antibodies targeting IFNGR1 are essential tools for studying its expression, function, and signaling mechanisms. Monoclonal and polyclonal antibodies against IFNGR1 are widely used in applications such as flow cytometry, immunohistochemistry, Western blotting, and ELISA to quantify receptor levels or assess cellular localization. These antibodies also enable research into IFNGR1-related pathologies, including primary immunodeficiencies caused by mutations in the IFNGR1 gene, which impair IFN-γ responsiveness and predispose individuals to severe infections. Additionally, IFNGR1 antibodies have therapeutic potential, with blocking antibodies explored in autoimmune diseases to suppress excessive IFN-γ signaling. Validation of antibody specificity, often confirmed via knockout cell lines or competitive binding assays, is crucial for experimental accuracy. Overall, IFNGR1 antibodies serve as indispensable reagents in both basic research and clinical investigations of immune dysregulation and infectious diseases.
×
